UPDATE : Monday, March 30, 2020
Celltrion licenses out hypertrophic cardiomyopathy treatment to Japan by Lee Han-soo 2019-03-25 15:41
Regulator OKs Medipost’s P1 trial of knee osteoarthritis treatment by Lee Han-soo 2019-03-22 14:22
Samsung Bioepis unveils 3-year follow-up data for Ontruzant by Lee Han-soo 2019-03-22 14:05
'US sales of Truxima imminent' by Jeong Sae-im 2019-03-20 17:59
Samsung BioLogics, Eutilex to develop anti-cancer immunotherapies by Lee Han-soo 2019-03-20 17:18
Samsung Bioepis nullifies patents related to Herceptin in Korea by Lee Han-soo 2019-03-18 15:51
Thea, OliX to cooperate in developing age-related macular degeneration treatment by Lee Han-soo 2019-03-18 12:02
CHA Biotech revises separate operating profit to a loss in 2018 by Jeong Sae-im 2019-03-15 16:26
'OliX to target global market with RNA technology' by Lee Han-soo 2019-03-15 11:44
Loss-making Medipost seeks to avoid administrative issue designation by Jeong Sae-im 2019-03-14 14:33
Celltrion Healthcare wins biosimilar bids in SE Asia by Lee Han-soo 2019-03-07 14:25
Biogen seeks gene therapy pipeline for rare eye disease by Kim Yun-mi 2019-03-06 14:41
Europe OKs Samsung Bioepis’ biosimilar treatment of breast cancer by Lee Han-soo 2019-03-05 17:53
Bridge Biotherapeutics to accelerate global presence by Lee Han-soo 2019-03-04 10:50
BioGenetics inks deal to supply biliary tract cancer drug in Korea by Lee Hye-seon 2019-02-28 16:49
Researchers find biomarker to predict recurrence of chronic myeloid leukemia by Park Gi-taek 2019-02-25 16:03
Celltrion Healthcare posts ₩713.5 billion in 2018 sales by Lee Han-soo 2019-02-22 17:29
Alteogen applies for P1 trial for Eylea biosimilar by Lee Han-soo 2019-02-22 16:03
Samsung Bioepis, C-Bridge Capital to develop biosimilars in China by Lee Han-soo 2019-02-11 11:23
Samsung BioLogics posts ₩535.8 billion in 2018 sales by Lee Han-soo 2019-02-01 11:56
Back to Top